A pharmacist fills a prescription. Photo: Jeffrey Greenberg / UIG via Getty Images

Lobbyists with the pharmacy benefit management industry met with federal officials last month, warning that Medicare Part D premiums will rise by 22% in 2019 if the government pursues an idea that would lower what Medicare patients pay for medications at the pharmacy counter.

Why it matters: PBMs and other companies that sell Medicare drug plans dislike the proposal, which would require them to apply rebates and fees at the point of sale as a way to make drugs cheaper, and a final ruling is expected soon.

The details: The meeting took place on Feb. 28, according to public records. Pharmaceutical Care Management Association CEO Mark Merritt and several other lobbyists affiliated with the PBM trade group attended.

Federal officials at the meeting included Joe Grogan, director of health programs at the White House's Office of Management and Budget, and numerous people with the Centers for Medicare & Medicaid Services, the agency that proposed the policy in November.

Merritt said in an interview the meeting was "mostly on issues where we had common ground," like opioid prescribing. But he and others voiced their opposition to point-of-sale rebates and reminded officials that President Trump's own budget said the measure would raise costs by $42 billion over the next decade.

Between the lines: The rebate proposal is only in an information-gathering phase, and independent analyses suggest it would in fact lead to higher Medicare premiums. But the Trump administration is hunting for any ways to ease drug costs, and the rebate idea would be an easy way for people to feel relief when they pick up their prescriptions.

Go deeper: Inside a drug pricing contract.

Go deeper

Updated 47 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Senate Democrats block vote on McConnell's targeted COVID relief bill McConnell urges White House not to strike stimulus deal before election.
  2. Economy: Why the stimulus delay isn't a crisis (yet).
  3. Health: Studies show drop in COVID death rate — The next wave is gaining steam — The overwhelming aftershocks of the pandemic.
  4. Education: Schools haven't become hotspots — San Francisco public schools likely won't reopen before the end of the year.

Senate Democrats block vote on McConnell's targeted COVID relief bill

Photo: Stefani Reynolds/Getty Images

Senate Democrats on Wednesday blocked a vote on Republicans' $500 billion targeted COVID-19 relief bill, a far less comprehensive package than the $1.8 trillion+ deal currently being negotiated between the Trump administration and House Democrats.

Why it matters: There's little appetite in the Senate for a stimulus bill with a price tag as large as what President Trump and House Speaker Nancy Pelosi have been calling for. Senate Majority Leader Mitch McConnell's (R-Ky.) "skinny" proposal was mostly seen as a political maneuver, as it had little chance of making it out of the Senate.

The hazy line between politics and influence campaigns

Illustration: Aïda Amer/Axios

The recent firestorm over the New York Post’s publication of stories relying on data from a hard drive allegedly belonging to Hunter Biden shows the increasingly hazy line between domestic political “dirty tricks” and a foreign-sponsored disinformation operation.

Why it matters: This haziness could give determined actors cover to conduct influence operations aimed at undermining U.S. democracy through channels that just look like old-fashioned hard-nosed politics.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!